- Home
- ZCMD vs XBIO Comparison
ZCMD vs XBIO Comparison
Compare ZCMD & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZCMD
- XBIO
- Stock Information
- Founded
- ZCMD 2012
- XBIO N/A
- Country
- ZCMD China
- XBIO United States
- Employees
- ZCMD N/A
- XBIO 4
- Industry
- ZCMD Other Consumer Services
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ZCMD Real Estate
- XBIO Health Care
- Exchange
- ZCMD Nasdaq
- XBIO Nasdaq
- Market Cap
- ZCMD 6.2M
- XBIO 6.3M
- IPO Year
- ZCMD 2020
- XBIO N/A
- Fundamental
- Price
- ZCMD $2.00
- XBIO $4.06
- Analyst Decision
- ZCMD
- XBIO Hold
- Analyst Count
- ZCMD 0
- XBIO 1
- Target Price
- ZCMD N/A
- XBIO N/A
- AVG Volume (30 Days)
- ZCMD 26.2K
- XBIO 22.9K
- Earning Date
- ZCMD 01-01-0001
- XBIO 11-12-2024
- Dividend Yield
- ZCMD N/A
- XBIO N/A
- EPS Growth
- ZCMD N/A
- XBIO N/A
- EPS
- ZCMD N/A
- XBIO N/A
- Revenue
- ZCMD $17,406,104.00
- XBIO $2,523,427.00
- Revenue This Year
- ZCMD N/A
- XBIO N/A
- Revenue Next Year
- ZCMD N/A
- XBIO N/A
- P/E Ratio
- ZCMD N/A
- XBIO N/A
- Revenue Growth
- ZCMD 1.01
- XBIO 7.15
- 52 Week Low
- ZCMD $1.00
- XBIO $2.78
- 52 Week High
- ZCMD $5.50
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- ZCMD 61.05
- XBIO 52.07
- Support Level
- ZCMD $1.91
- XBIO $3.92
- Resistance Level
- ZCMD $1.47
- XBIO $4.27
- Average True Range (ATR)
- ZCMD 0.27
- XBIO 0.25
- MACD
- ZCMD 0.07
- XBIO -0.04
- Stochastic Oscillator
- ZCMD 61.24
- XBIO 38.45
About ZCMD Zhongchao Inc.
ZHONGCHAO Inc is a Cayman Islands-based provider of healthcare information, education, and training services. It provides services to healthcare professionals and the public in China. It offers online and onsite health information services, healthcare education programs, and healthcare training products, consisting of clinical practice training, open classes of popular medical topics, interactive case studies, academic conferences and workshops, continuing education courses, and articles and short videos with educational healthcare content.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.